# Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

> **NCT05330286** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** LMI070
- **DRUG:** LMI070
- **DRUG:** LMI070
- **DRUG:** LMI070

## Key facts

- **NCT ID:** NCT05330286
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-13
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-08-19
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The compound is no longer suitable for further clinical development due to a safety finding in a later phase program.
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330286, "Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05330286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*